Business Context and Reporting Period
Company: Intensity Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: October 30, 2025
Reporting Period: Specific event date of October 30, 2025, with expected closing on or about November 3, 2025.
The Company, an emerging growth company incorporated in Delaware, entered into a Securities Purchase Agreement to conduct a registered direct offering of common stock.
Key Financial Metrics and Transaction Details
| Metric | Value |
|---|---|
| Shares Issued | 5,000,000 |
| Offering Price | $0.80 per share |
| Gross Proceeds | $4.0 million |
| Placement Agent Fee | 7.0% of gross proceeds |
| Legal Expense Reimbursement Cap | $50,000 |
Liquidity Impact: The transaction is expected to provide $4.0 million in gross proceeds to the Company, subject to deduction of placement agent fees and offering expenses. The filing does not provide current cash balance, debt levels, or operating margins.
Material Changes and Agreements
- Securities Purchase Agreement: Entered into on October 30, 2025, with an institutional investor for the sale of 5,000,000 shares of Common Stock.
- Placement Agent Agreement: Engaged A.G.P./Alliance Global Partners as the placement agent. The agent receives a 7.0% cash fee and reimbursement for out-of-pocket expenses, including legal fees up to $50,000.
- Issuance Restrictions: The Company agreed to restrictions on issuing Common Stock or Common Stock Equivalents for a 30-day period following the closing of the Offering.
- Registration: The offering utilizes a Registration Statement on Form S-3 (File No. 333-280681) declared effective on July 11, 2024.
Outlook, Risks, and Management Commentary
Outlook: The Offering is expected to close on or about November 3, 2025, subject to customary closing conditions. A pricing press release was issued on October 31, 2025.
Risks and Contingencies: The filing notes that the sale of securities is subject to state and federal securities laws. The Company is subject to a 30-day lock-up period regarding further issuances. The filing does not contain specific management commentary on operational risks or future guidance beyond the transaction details.
Investor Verification Checklist
- Verify the final closing date of the Offering (expected November 3, 2025) and confirmation of fund receipt.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and representations.
- Confirm the exact amount of net proceeds after deducting the 7.0% placement fee and legal expenses.
- Monitor the Company's capitalization table for the impact of the 5,000,000 new shares on existing shareholder dilution.
- Check for any subsequent filings regarding the satisfaction of closing conditions.